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Evidence to date suggests the consumption of food rich in bioactive compounds,
such as polyphenols, flavonoids, omega-3 fatty acids may potentially minimize agerelated cognitive decline. For neurodegenerative diseases, such as Alzheimer’s disease
(AD), which do not yet have definitive treatments, the focus has shifted toward using
alternative approaches, including prevention strategies rather than disease reversal. In
this aspect, certain nutraceuticals have become promising compounds due to their
neuroprotective properties. Moreover, the multifaceted AD pathophysiology encourages
the use of multiple bioactive components that may be synergistic in their protective roles
when combined. The objective of the present study was to determine mechanisms of
action underlying the inhibition of Aβ1−42 -induced toxicity by a previously determined,
three-compound nutraceutical combination D5 L5 U5 for AD. In vitro experiments were
carried out in human neuroblastoma BE(2)-M17 cells for levels of ROS, ATP mitophagy,
and mitobiogenesis. The component compounds luteolin (LUT), DHA, and urolithin A
(UA) were independently protective of mitochondria; however, the D5 L5 U5 preceded
its single constituents in all assays used. Overall, it indicated that D5 L5 U5 had potent
inhibitory effects against Aβ1−42 -induced toxicity through protecting mitochondria.
These mitoprotective activities included minimizing oxidative stress, increasing ATP
and inducing mitophagy and mitobiogenesis. However, this synergistic nutraceutical
combination warrants further investigations in other in vitro and in vivo AD models to
confirm its potential to be used as a preventative therapy for AD.
Keywords: mitobiogenesis, mitochondrial dysfunction, mitophagy, reactive oxygen species, synergistic
nutraceutical combination, Alzheimer’s disease
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is reported to modulate mitochondrial biogenesis, which is
partially associated with increased mtDNA replication and
PGC-1α gene expression in C2C12 muscle cells (Lee et al., 2016)
and in C57BL/6J mice (Flachs et al., 2005). There is evidence that
DHA promotes apoptosis and autophagy, however, there are no
reports to date on its effect on mitophagy, which is the selective
autophagy of superfluous mitochondria (Lemasters, 2005;
Kubli and Gustafsson, 2012). The protective effects of LUT are
associated with up-regulation of autophagy and improvement
of mitochondrial biogenesis through Mst1 inhibition (Hu
et al., 2016). Furthermore, LUT has exerted neuroprotection
by enhancing autophagy and anti-oxidative processes in both
in vivo and in vitro models of intracerebral hemorrhage (Tan
et al., 2020). Luteolin has been recently reported to induce
mitochondrial apoptosis in HT29 cells by inhibiting the
Nrf2/ARE signaling pathway (Yang et al., 2020). Furthermore,
LUT has protected endothelial cells against H2 O2 -induced
oxidative stress via modulating ROS-mediated P38 MAPK/NFκB and calcium-evoked mitochondrial apoptotic signaling
pathways (Chen et al., 2020). However, evidence is scarce
that LUT improves mitochondrial dynamics and mitophagy.
It is increasingly identified that UA restores mitochondrial
dysfunction in the aging skeletal muscle through up-regulation
of genes associated with mitochondrial biogenesis, mitophagy
and fatty acid oxidation (Yang, 2019). Recently, it has been
proven in C57BL/6 male mice fed on high fat diet that UA
resulted in elevated mitochondrial biogenesis in the liver (Toney
et al., 2019) along with inducing mitophagy (Ryu et al., 2016).
One study reported that mitophagy is not induced by UA in
both ischemia/reperfusion−injured neuronal cells and mice
(Ahsan et al., 2019). Therefore, further studies are still needed
to confirm the mitophagy-inducing potential of UA. Taken
collectively, these previous reports on mitoprotective effects of
DHA, LUT, and UA provide further motivation to investigate if
the beneficial effects still exist when the same are combined in
low concentrations.
The present study was undertaken to evaluate the in vitro
pathways D5 L5 U5 take to protect against Aβ1−42 -induced
toxicity. For comparison, the components of this combination,
DHA, LUT, and UA were also assessed for their ability to protect
from Aβ1−42 -induced toxicity.

INTRODUCTION
Alzheimer’s disease (AD) is the most common form of dementia
that constitutes approximately 60–80% of clinically diagnosed
dementia cases, worldwide (Alzheimer’s Association, 2020). The
need for an effective treatment for AD is critical, especially
considering the rapidly growing number of people living with
the disease and the associated socioeconomic impact (Alzheimer’s
Association, 2020). However, there is currently limited success
in clinical trials, with most ending in failure (Oxford et al.,
2020). Most of the criticisms are attributed to the targeting of the
clinical phenotype, where there is existing irreversible synaptic
and neuronal degeneration and profound inflammatory changes
(Huang et al., 2020). Other than the controversies related to
very recently approved drug Aducanumab (Selkoe, 2021), the
current situation where there is still no AD-targeted-therapy
pending approval soon emphasizes the need for identification
of AD preventive strategies. This approach targeting prevention
is the most appealing, considering the long prodromal phase of
AD, that can span more than 10 to 20 years before clinical signs
of AD appear (Villemagne et al., 2013). As illustrated by Hodes
et al. (2019), there is an ongoing debate over the use of the terms
“prevention” and “risk reduction” in AD (Hodes et al., 2019).
However, in either case of preventing or delaying the related
cognitive decline, AD onset and progression requires a clinical
intervention and alternative, preferably non-pharmacological,
options have become increasingly attractive.
Lifestyle is thought to be one of the key modifiable risk factors
for AD, with diet playing a major role (Hu et al., 2013). Thus,
diet is important as a potential target for the development of
preventive strategies for AD (Dadhania et al., 2016). The bioactive
components of diets, the nutraceuticals (Kalra, 2003), are
being investigated for their capabilities in preventing AD onset
and progression (Farías et al., 2014). Accumulating evidence
suggests that nutraceuticals, such as polyphenols and specific
fatty acids found in fruits, vegetables, herbs, and nuts may
slow neurodegeneration and improve memory and cognitive
function (Joseph et al., 2009; Mecocci et al., 2014; Keservani
et al., 2016). Furthermore, nutraceutical combinations can be
the most effective, as they may act synergistically against the
multiple aspects of AD pathogenesis. In general, the different
phytochemicals in a nutraceutical combination can activate
different cellular pathways by improving the bioavailability
of active compounds. Thus, an advantage of a synergistic
nutraceutical combinations is the possibility to reduce doses of
individual compounds resulting in toxic effects at minimum
(Santana-Gálvez et al., 2019). Therefore, synergistic nutraceutical
combinations can be used to formulate novel and effective
functional food products with anti-AD properties.
Recently, we identified a three-compound synergistic
nutraceutical combination D5 L5 U5 that exhibited synergistic
activity against Aβ1−42 -induced toxicity in cell culture (Jayatunga
et al., 2021). It consisted of three nutraceutical compounds
docosahexaenoic acid (DHA), luteolin (LUT), and urolithin
A (UA) each at 5 µM concentration. These constituents were
considered in deciphering a probable mechanism of action
for this nutraceutical combination. Docosahexaenoic acid
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MATERIALS AND METHODS
Materials
cis-4,7,10,13,16,19-Docosahexaenoic acid (DHA: D2534), LUT
(L9283), UA (SML1791), N-acetyl L-Cysteine (NAC: A9165),
Resveratrol (RES), Bafilomycin A (Baf A: B1793), sodium
docecyl sulfate (SDS), Triton X-100, and dimethyl sulfoxide
(DMSO) were obtained from Sigma Aldrich, United States.
BE(2)-M17 cells (ATCC CRL2267TM ) were purchased from
American Type Cell Culture Collection (ATCC, Manassas, VA,
United States). All cell culture reagents including Dulbecco’s
Modified Eagle Medium (DMEM), Ham’s F12 medium, Hank’s
balanced salt solution (HBSS), fetal calf serum (FCS) and
Trypsin-EDTA (0.5%) were purchased from GIBCO by Life
R
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Technologies (United States). Human Aβ1−42 peptides were
synthesized, purified and characterized by high pressure
liquid chromatography (HPLC) and mass spectrometry
(MS) by The ERI Amyloid Laboratories LLC, United States.
Anhydrous DMSO was purchased from Molecular Probes by
Life Technologies (United States). CellTiter-Glo luminescent
cell viability assays were purchased from Promega, Wisconsin,
United States and 20 ,70 -dichlorofluorescin diacetate (DCFDA)
intracellular ROS assay kits (ab113851) were obtained from
Abcam, Cambridge, United Kingdom. Bolt 4–12% Bis-Tris
plus gels, gel running MES [2-(N-morpholino) ethanesulfonic
acid] buffer, 4X Bolt Lithium dodecyl sulfate (LDS) sample
buffer NuPAGE, 10X Bolt sample reducing agents, Novex
Sharp pre-stained protein standards were purchased from Life
Technologies, United States. Primary antibodies, p62, PINK1,
TOMM20, TIMM23, FIS1, and PGC-1α and goat anti-rabbit
Alexa Fluor488 secondary antibody were obtained from Abcam,
Cambridge, United Kingdom. Primary antibodies, LC3B, MFN2,
NDP52, OPTN and OPA1 were obtained from Cell Signaling. For
Western blotting, trans blot turbo mini nitrocellulose transfer
packs were purchased from Biorad, United States. Secondary
antibodies, anti-mouse and anti-rabbit immunoglobulin G (IgG)
horse radish peroxidase (HRP) linked whole antibodies and
enhanced chemiluminescence (ECL) kits were obtained from GE
Healthcare, United Kingdom.

Treatments
In all treatments, the cells were pre-treated with the compound
combination D5 L5 U5 (DHA 5 µM, LUT 5 µM, and UA 5 µM)
and the individual compounds, DHA (30 µM), LUT (20 µM),
and UA (30 µM) for 24 h. These concentrations of DHA, LUT,
and UA were selected based on our previous studies (Jayatunga
et al., 2021). Resveratrol (RES) was used as a positive control in
all experiments as it is a known agent of inducing mitochondrial
dynamics, mitophagy and mitobiogenesis. N-acetyl cysteine
(NAC) is an antioxidant that was used as a reference compound
for ROS analysis. The concentrations of RES and NAC used in the
experiments were based on the available literature (Mitsopoulos
and Suntres, 2011; Gueguen et al., 2015).
In all experiments, after pre-treatment with the compounds
was followed by 20 µM oligomeric Aβ1−42 treatment for 16 h
unless otherwise specified. This time period was selected based
on our previous findings that mitophagy is diminished after 16 h
of 20 µM Aβ1−42 treatment in BE(2)-M17 cells (Jayatunga et al.,
unpublished). All treatments were carried out with appropriate
Aβ1−42− treated and vehicle-treated controls.

DCFDA Assay
The BE(2) M17 cells seeded in 96 well plates at a density
of 25 × 103 cells/well. After 24 h, the cells were pre-treated
with the compounds for 24 h. The cells were then exposed to
20 µM Aβ1−42 for 4 h in the incubator at 37◦ C and intracellular
ROS levels were determined using the DCFDA assay. Aβ1−42
incubation of 4 h was based on our previous work (Jayatunga
et al., unpublished). Briefly, 45 min prior to completion of
the treatment, the cells in color-free treatment media (100 µL
per well) were overlaid with 100 µL of warm 50 µM DCFDA
solution [diluted from the DCFDA stock (20 mM) using 1X
wash buffer]. The microplate was incubated for 45 min at
37◦ C and fluorescence readings (Relative Fluorescence Units:
RFU at excitation 485 nm/emission 535 nm) were obtained at
excitation 485 and 535 nm using a Perkin Elmer EnSpire multimode plate reader.

Cell Culture
Human neuroblastoma BE(2)-M17 cells were maintained in
T75 culture flasks containing 15 mL of DMEM/F12 (1:1 ratio)
growth media supplemented with 10% (v/v) FCS and placed in
a humidified incubator with 5% CO2 /95% air at 37◦ C. Upon
reaching about 80% confluency, the cells were sub-cultured on to
fresh cell culture flasks. For all cell culture experiments, passage
number did not exceed 30.

Aβ1−42 Peptide Preparation
Oligomeric Aβ1−42 was prepared according to the method of
Stine et al. (2011) with some modifications. Briefly, synthetic
human Aβ1−42 peptide of 4.5 mg was dissolved in 1000 µL
HFIP solution and incubated for 30 minutes at room temperature
(RT). The Aβ1−42 dissolved HFIP solution was aliquoted using
positive displacement pipetting, into 10 microcentrifuge tubes
each containing 0.45 mg Aβ1−42 peptide. The aliquots were
then air-dried in a fume cupboard overnight at RT. The tubes
containing the peptide films were further dried in a Savant
vacuum concentrator (–80 ◦ C). The Aβ1−42 films were then
stored at –30 ◦ C in a sealed container with desiccant. All Aβ1−42
peptide solutions were freshly prepared for each experiment. The
0.45 mg peptide film in the tube was dissolved in 20 µL of
anhydrous DMSO (Molecular probes). The solution was briefly
vortexed, then sonicated in a water bath for 10 minutes with
temperature controlled by adding ice so as not to exceed RT.
Then, 980 µL of ice-cold F12 media (without phenol red) was
added. The solution was then briefly vortexed and incubated for
24 hours at 4 ◦ C to be used in Aβ1−42 toxicity experiments the
next day.

Frontiers in Aging Neuroscience | www.frontiersin.org

CellTiter Glo Assay
The BE(2)-M17 cells were seeded in 96-well plates at a density of
15 × 103 cells/well. After 24 h, the cells were pre-treated with the
compounds for 24 h. After exposure of 20 µM Aβ1−42 for 4, 8,
16, 24, 48, and 72 h, the CellTiter Glo assay was used to determine
relative ATP levels. Briefly, cells were placed at RT for 30 min and
then lysed by adding 100 µL of ATP-releasing reagent. The lysates
were incubated with the luciferin substrate and luciferase enzyme
in the dark for 10 min to stabilize the luminescence signal. The
luminescence (RLU) was measured using a Perkin Elmer EnSpire
multi-mode plate reader.

Western Blot Analyses
The BE(2)-M17 cells were seeded in T25 cell culture flasks at
a density of 1 × 106 cells per flask and grown for 24 h. Test
samples were prepared by compound pre-treatments followed by
20 µM oligomeric Aβ1−42 treatments for 16 h. Additionally, for
p62, NDP52 and OPTN, Bafilomycin A (Baf A) was added to
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the cell flasks after 15 h, i.e., 1 h prior to reaction completion.
The cells were lysed in precooled lysis buffer (SDS: Triton X100, 7:3, protease inhibitor, PBS) and protein concentrations
were determined using a BCA protein assay kit. Protein samples
were separated on 4–12% Bis-Tris gels by polyacrylamide gels
electrophoresis (SDS-PAGE) and transferred onto nitrocellulose
membranes. Then, membranes were blocked in 5% non-fat milk
for 30 min at room temperature and incubated with primary
antibodies (rabbit monoclonal MFN2 antibody; 1:1,000, rabbit
monoclonal OPA1 antibody; 1:2,000, rabbit monoclonal FIS1
antibody; 1:5,000, mouse monoclonal p62 antibody; 1:2,000,
rabbit polyclonal LC3B antibody; 1:1,000, rabbit polyclonal
PINK1 antibody; 1:1,000, rabbit monoclonal NDP52 antibody;
1:1,000, rabbit monoclonal OPTN antibody; 1:500, rabbit
polyclonal TIMM23 antibody; 1:200, mouse monoclonal PGC1α antibody; 1:1,000) overnight at 4◦ C. Membranes were then
washed and incubated with HRP-conjugated goat anti-rabbit and
HRP-conjugated goat anti-mouse (1:5,000) secondary antibodies
for 1 h at room temperature followed by development using ECL
detection. The protein bands were normalized against GAPDH,
using ImageLab program (Biorad; v. 6.0.1).

Statistical Analysis
All results were expressed as mean ± standard deviation
(SD) from four (N = 4) independent experiments. Statistical
significance was determined by one-way ANOVA and Tukey’s
post hoc test in SPSS v25. Significance was defined as P < 0.05.

RESULTS
D5 L5 U5 , DHA, Luteolin, and Urolithin A
Reduce Aβ1−42 -Induced ROS Levels
In the DCFDA cellular ROS assay, the ROS level of vehicle
control was considered as 100%. The treatment of 20 µM
Aβ1−42 significantly increased ROS levels at 4 h to 124.8 + 4.0%
(P < 0.05), however, D5 L5 U5 , DHA, LUT, and UA significantly
decreased ROS levels to 101.6 + 6.6% (P < 0.001), 95.7 + 4.1%
(P < 0.001) and 111.7 + 5.9% (P < 0.05), respectively (Figure 1).
Surprisingly however, RES resulted in further increased ROS level
of 159.8 + 1.4% (P < 0.001). As expected, NAC significantly
reduced the ROS levels to 58.4 + 6.4% (P < 0.001), while TBHP

FIGURE 1 | The effect of the three-compound combination and the optimal concentrations of its components against Aβ1−42 -induced ROS levels. The BE(2)-M17
cells were pre-treated for 24 h with D5 L5 U5 , LUT, DHA, and UA. Resveratrol (RES) was used at a concentration of 10 µM. Tertbutyl hydrogen peroxide (TBHP)
50 µM and NAC 5 mM were used as positive and negative controls for the assay. The cells were then exposed to 20 µM of oligomeric Aβ1−42 for 4 h to induce ROS
production. Black bars indicate the ROS production in the presence of 20 µM Aβ1−42 while the white bars indicate the ROS production in the presence of 20 µM
Aβ1−42 . Cellular ROS levels were evaluated in relative fluorescence units (RFU) using the DCFDA assay. Data are expressed as mean ± SD from four (N = 4)
independent experiments. Differences are significant at # P < 0.05, ### P < 0.001 vs. vehicle control. *P < 0.05, ***P < 0.001vs. Aβ1−42 -treated control.
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FIGURE 2 | The time-dependent effects of the three-compound combination and its components on oligomeric Aβ1−42 -affected ATP levels. The BE(2)-M17 cells
were pre-treated for 24 h with D5 L5 U5 , LUT, DHA, and UA. Exposure of 20 µM oligomeric Aβ1−42 was carried out for different time points (4–72 h) at 37◦C and
relative ATP levels were detected as relative luminescence units (RLU) using CellTiter Glo assay. Data are expressed as mean ± SD from four (N = 4) independent
experiments. Differences are significant at **P = 0.001, ***P < 0.001 vs. untreated, b P < 0.05, c P = 0.001, a P < 0.001 vs. Aβ1−42 -treated controls.

FIGURE 3 | The effect of the three-compound combination and its components on the levels of L-OPA1 and S-OPA1. The BE(2)-M17 cells were pre-treated for 24 h
with the three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric
Aβ1−42 for 16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of L-OPA1/S-OPA1 proteins for all treatments.
The relative density of the bands was normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from
four (N = 4) independent experiments. Differences are significant at b P < 0.05 vs. vehicle control, *P < 0.05, ***P < 0.001, a P < 0.001 vs. Aβ1−42 -treated controls.
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per se increased the ROS levels to 268.5 + 10.6%, compared to
vehicle control (P < 0.001).

D5 L5 U5 , Luteolin, and Urolithin A
Restores Aβ1−42 -Induced Reduction of
ATP Levels
As shown in Figure 2, the treatment of 20 µM Aβ1−42 timedependently decreased cellular ATP levels in cells at 48 h
(P = 0.001) and 72 h (P < 0.001). However, pre-treatment with
D5 L5 U5 , LUT, and UA caused increased ATP levels at each time
point while DHA did not alter the decreased ATP levels. These
results indicated that D5 L5 U5 , LUT, and UA increase the ATP
levels of cells exposed to Aβ1−42 (Figure 2).

D5 L5 U5 Increases Mitochondrial Fusion
Protein S-OPA1 and Decreases Fission
Protein FIS1
Mitochondrial fusion proteins, OPA1 and MFN2 and the
mitochondrial fission proteins FIS1 were evaluated in analyzing
mitochondrial dynamics. The 20 µM Aβ1−42 treatment
significantly decreased L-OPA1 and S-OPA1 levels (P < 0.05 and
P < 0.001, respectively). However, pre-treatments with DHA,
LUT, UA and RES increased L-OPA1 levels (P < 0.001, P < 0.05,
P < 0.001, and P < 0.001) while D5 L5 U5 , DHA, UA, and RES
increased S-OPA1 levels (P < 0.05, P < 0.001, P < 0.001, and
P < 0.001) (Figure 3). These results indicate that D5 L5 U5 , DHA,
LUT, UA, and RES all increase OPA1 levels in general.
Treatment of 20 µM Aβ1−42 markedly decreased the MFN2
levels (P < 0.001) indicating that Aβ1−42 treatment inhibits
the mitochondrial fusion process at 16 h, however, pre-treating
with DHA and RES increased the MFN2 levels (P < 0.001,
P < 0.05) while pre-treatment with D5 L5 U5 did not give any
change (Figure 4).
The treatment of 20 µM Aβ1−42 caused a reduced
trend in the FIS1 levels which is indicative of reduced
mitochondrial fission process. However, all the compound
treatments failed to restore the FIS1 levels, instead, D5 L5 U5 , and
DHA resulted in significantly reduced FIS1 levels (P < 0.001 and
P < 0.05) (Figure 5).

FIGURE 4 | The effect of three-compound combination and its components
on the levels of MFN2. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA
(30 µM), and RES (10 µM). The cells were then exposed to 20 µM of
oligomeric Aβ1−42 for 16 h and subjected to Western blotting. The
representative immunoblot and the graph indicate the levels of MFN2 protein
for all treatments. The relative density of the bands was normalized against
GAPDH. Fold values were calculated relative to vehicle control. Data are
expressed as mean ± SD from four (N = 4) independent experiments.
Differences are significant at c P < 0.001, # P < 0.05, ### P < 0.001 vs.
Aβ1−42 -treated control.

A) results in increased level of a degradable autophagosomal
protein (e.g., p62, NDP52, OPTN) compared to that of the
treatment and the Baf A-only group, it can be considered
that the selective treatment enhances autophagic flux (Klionsky
et al., 2016). Similarly, if the relevant protein level of lysosomal
blockade of a certain treatment is higher than that of the Baf
A-only group, it can be deemed that the treatment increases
synthesis of autophagy-related membranes. On the other hand,
if the treatment results in lower levels of the relevant protein
compared to its lysosomal blockade (with Baf A), the treatment
is considered to induce a partial block in autophagic flux. If
these two entities are similar, a complete blockade of autophagy
at the terminal stages is expected (Klionsky et al., 2016).
These factors were made use in inferring mitophagy in the
present study. However, consistent results could not be obtained
for LC3I/II blots.
As shown in Figure 6, the insult of 20 µM Aβ1−42
for 16 h significantly decreased p62 levels (P < 0.05),
representing a decrease in mitophagy (Klionsky et al., 2016).
Furthermore, decrease of intensity in Baf A-treated Aβ1−42
control relative to Baf A-treated vehicle (P < 0.001) further
confirmed that the exposure of 20 µM Aβ1−42 caused the
increased synthesis of autophagy-related membranes. Pretreatments with DHA, LUT, UA, and RES significantly increased
p62 levels (P = 0.001, P < 0.001, P = 0.001 and P < 0.001)

Urolithin A, Luteolin, and DHA Induces
Mitophagy and D5 L5 U5 Increases the
Mitophagy Protein NDP52 but Not the
Mitophagic Flux
The present study evaluated the impact of the test compounds
on mitophagy to assess their activity on protecting against
the Aβ1−42 -induced effect on mitophagy. To achieve this,
the expression levels of a panel of mitophagy-related proteins
including LC3-I/II, p62, NDP52, OPTN, PINK1, and IMM
protein TIMM23 was assessed. For p62, NDP52, OPTN,
additional treatments were carried out with Bafilomycin A (Baf
A)-mediated lysosomal blockade to examine the transit of the
mitophagy adaptors through the autophagy pathway. Under
lysosomal blockade, it has been reported by Klionsky et al. (2016),
that if a lysosomal blockade of a certain treatment (with Baf
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FIGURE 5 | The effect of three-compound combination and its components on the levels of FIS1. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of FIS1 protein for all treatments. The relative density of the
bands was normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent
experiments. Differences are significant at $ P < 0.05, $$$ P < 0.001 vs. Aβ1−42 -treated controls.

resulting in a comparable level to that of lysosomal blockade (Baf
A-treated RES) is indicative of complete block in mitophagy at
the terminal stages.
The treatment of 20 µM Aβ1−42 for 16 h significantly
decreased OPTN levels (P < 0.001) indicating decreased
mitophagy. Furthermore, decreasing of Aβ1−42 control
with lysosomal blockade (Baf A-treated) relative to Baf
A-treated vehicle (P < 0.05) further confirmed that exposure
of 20 µM Aβ1−42 decreased the synthesis of autophagyrelated membranes. Pre-treatments with DHA, LUT, UA, and
RES significantly increased OPTN levels (P < 0.001 each)
reflecting an induction of mitophagy. Moreover, considering
lysosomal blockade, increased OPTN levels for Baf A-treated UA
(P < 0.05) suggested increased synthesis of autophagy-related
membranes. However, RES and LUT resulting in unaltered
OPTN levels for Baf A-treatments suggest a complete block of
autophagy/mitophagy at the terminal stages. DHA resulting
in decreased OPTN for Baf A-treatment (P < 0.05 each)
implicated that a partial block in autophagic flux is induced by
DHA (Figure 8).

suggesting the induction of mitophagy. Similarly, considering
the lysosomal blockade by Baf-A, p62 levels were increased
by DHA, UA, and RES (P < 0.001 each) relative to Baf
A-treated Aβ1−42 treatment, suggesting that pre-treatment with
these compounds increased the synthesis of autophagy-related
membranes (Klionsky et al., 2016).
The 20 µM Aβ1−42 treatment for 16 h significantly decreased
the levels of mitophagy adaptor protein NDP52 (P < 0.001)
indicating diminished mitophagy. However, pre-treatments with
D5 L5 U5 , DHA, and LUT significantly increased NDP52 levels
(P < 0.001 each) (Figure 7) reflecting increased mitophagy by
these compounds. However, for D5 L5 U5 , DHA, and LUT, the
NDP52 levels with the lysosomal blockade (with Baf A-treatment)
were not significantly increased relative to Baf A-untreated
for D5 L5 U5 , DHA and LUT suggesting a possible block in
autophagy/mitophagy at the terminal stages. On the other
hand, the snapshot NDP52 levels for UA showing a statistically
significant increase and lysosomal blockade for UA (Baf A-treated
UA) resulting in higher NDP52 levels suggest that mitophagic
flux is increased for UA. On the other hand, NDP52 level for RES
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FIGURE 6 | The effect of the three-compound combination and its components on the levels of p62. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of p62 protein for all treatments. Black bars indicate the
p62 levels in the presence of bafilomycin A (Baf A) while the white bars indicate the p62 levels in the absence of Baf A. The relative density of the bands was
normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent experiments.
Differences are significant at d P < 0.05 vs. vehicle control, **P = 0.001, ***P < 0.001 vs. Aβ1−42 -treated control.

As shown in Figure 9, 20 µM Aβ1−42 treatment markedly
decreased PINK1 levels (P < 0.001) suggesting that Aβ1−42
causes a mitophagy deficit in PINK1/Parkin-mediated mitophagy
pathway. However, pre-treatments with DHA, LUT, UA, and RES
increased the PINK1 levels (P < 0.05, P < 0.05, P < 0.05, and
P < 0.001). These results support the notion that DHA, LUT, UA,
and RES may induce mitophagy possibly through PINK1/Parkin
mediated pathway.
The treatment of 20 µM Aβ1−42 for 16 h showed no
significant difference in the TIMM23 levels compared to the
untreated. Considering the TIMM23 levels as a marker of
number of mitochondria, the stable TIMM23 levels suggest
three possibilities. First, reduced mitophagy and mitobiogenesis.
Second, an increase of both processes and thirdly, no change
is both the processes. Similarly, the pre-treatments with
D5 L5 U5 and DHA did not alter the levels of TIMM23
(Figure 10). On the other hand, LUT, UA and RES markedly
decreased the TIMM23 levels (P < 0.001 each) when compared
to the Aβ1−42 -treated control. A reduction in TIMM23
levels can be a consequence of enhanced mitophagy or
impairments in the mitochondrial biogenesis. Therefore, for
further inference, the effects of the compounds on mitobiogenesis
were evaluated next.

Frontiers in Aging Neuroscience | www.frontiersin.org

D5 L5 U5 Increases Mitochondrial
Biogenesis-Related Protein PGC1-α
Mitobiogenesis was evaluated in the present study by quantifying
PGC1-α. As shown in Figure 11, exposure of 20 µM Aβ1−42
for 16 h did not alter the levels of PGC1-α indicating that
mitobiogenesis is not affected. However, pre-treatment with
D5 L5 U5 (P < 0.05) and DHA elevated PGC1-α levels with the
latter resulting in a marked increase (P < 0.001) reflecting their
increased ability to induce mitobiogenesis. These results taken
together with the findings of altered TIMM23 levels (Figure 10)
provide some insight of these compounds on mitophagy.
The results summarized in the Table 1 shows that after 16 h
of Aβ1−42 exposure, the dynamics-related proteins L-OPA1,
S-OPA1, MFN2, and FIS1 and the mitophagy proteins, p62,
OPTN, and PINK1 all decreased. These results, along with
the increased TIMM23 levels at 16 h indicate that there is
a deficit in mitophagy in response to 16 h Aβ1−42 exposure.
However, the three-compound combination resulted in increased
NDP52/PINK1 and PGC-1α levels indicating its ability to induce
mitophagy and mitobiogenesis, respectively. Treatment with
DHA increased OPA1 levels, p62/NDP52/OPTN/PINK1 levels
and PGC-1α, indicating its activity in increasing mitochondrial
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FIGURE 7 | The effect of the three-compound combination and its components on the levels of NDP52. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of NDP52 protein for all treatments. Black bars indicate the
NDP52 levels in the presence of bafilomycin A (Baf A) while the white bars indicate the NDP52 levels in the absence of Baf A. The relative density of the bands was
normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent experiments.
Differences are significant at e P < 0.001 vs. vehicle control, ### P < 0.001 vs. Aβ1−42 -treated controls.

this light, the present study explored the neuroprotective action
of D5 L5 U5 .
In AD, excessive ROS is generated from impaired
mitochondria as well as through Aβ interactions with transition
metal ions. In fact, abnormal accumulation of Aβ and Tau
proteins promote redox imbalance leading to oxidative
stress. However, existing antioxidants have been shown to
be relatively ineffective in combating AD (Lloret et al., 2011;
Lloret et al., 2019). There may be several reasons for this. First,
the antioxidants may not be able to cross the BBB and reach the
specific sites of ROS release in the brain, which are suggested to
be the hydrophobic domains within mitochondrial membranes.
Second, the antioxidants may have a poor ability to scavenge
ROS. The present study used the DCFDA assay to determine
ROS in the cells. The DCFDA reagent diffuses into cells and gets
deacetylated by cellular esterases to a non-fluorescent compound
that gets oxidized to a fluorescent compound by cellular ROS.
The results revealed that D5 L5 U5 as well its components, DHA,
LUT, and UA, decreased the cellular ROS levels, generated by 4 h
of exposure of 20 µM Aβ1−42 . The potency of the antioxidant
activity was, LUT > D5 L5 U5 > DHA > UA (Figure 1).
Luteolin showed the highest antioxidant activity in the present
study (Figure 1). It is consistent with previous reports indicating
antioxidant effects of LUT (Xiao et al., 2019). Furthermore,

fusion, mitophagy and mitobiogenesis. LUT resulted in increased
L-OPA1 and p62/NDP52 levels reflecting its ability to induce
mitochondrial fusion and mitophagy, respectively. Finally, UA
was shown to induce mitochondrial fusion and mitophagy due
to increased OPA1 levels and p62/OPTN levels, respectively.

DISCUSSION
Evidence is accumulating that a healthy diet enriched with
bioactive components have a protective role in reducing the
risk of AD. The current study presented a comprehensive cellbased investigation of the therapeutic effects of a previously
determined nutraceutical combination, D5 L5 U5 (Jayatunga et al.,
2021) against Aβ1−42 -induced toxicity. As per the initial test
results of MTS and ATP assays, the combination was anticipated
to have beneficial effects on mitochondria. On the other
hand, mitochondrial dysfunction is an important feature in
Aβ1−42 -induced toxicity (Chen and Yan, 2007). Dysfunctional
mitochondria are often portrayed by increased oxidative
stress and deficits in mitochondrial dynamics, mitophagy and
mitochondrial biogenesis. Therefore, inducing these processes
are important therapeutic targets in AD (Su et al., 2010;
Uittenbogaard and Chiaramello, 2014; Jayatunga et al., 2020). In
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FIGURE 8 | The effect of the three-compound combination and its components on the levels of OPTN. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of OPTN protein for all treatments Black bars indicate the
OPTN levels in the presence of bafilomycin A (Baf A) while the white bars indicate the OPTN levels in the absence of Baf A. The relative density of the bands was
normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent experiments.
Differences are significant at f P < 0.001 vs. vehicle control, $$$ P < 0.001 vs. Aβ1−42 -treated control.

intracellular ROS levels and increase intracellular SOD and GPx
activity in vitro (Wang et al., 2015). However, UA has been
shown to exert pro-oxidant activities as well (Kallio et al., 2013).
Moreover, at higher concentrations, a bi-phasic effect of DHA
has also been reported in human blood platelets due to its prooxidant effects (Vericel et al., 2003). Luteolin is also reported to
act as a pro-oxidant as part of its redox modulation activity (Lin
et al., 2008). Thus, the three-compound combination, D5 L5 U5
may also potentially have a pro-oxidant activity, however, it
was not evaluated in the present study. It must be noted
that the redox properties of compounds are highly reliant on
the reaction conditions and employed assay system. Hence, it
is important to study both the pro-oxidant and antioxidant
activities simultaneously if possible (Kallio et al., 2013).
Apart from the above-mentioned ROS scavenging antioxidant
strategies, the ability to directly block mitochondrial ROS
production may be an effective way of inhibiting oxidative
stress. Whist, it seems challenging to define both the normal
and pathologically relevant ROS formation, lowering of ROS
production by efficiently stabilizing mitochondrial energy
production appears feasible. In healthy mitochondria, ATP,
and ROS levels are coupled. However, it has been reported
that a mild mitochondrial uncoupling (resulting in increased
ATP levels and decreased ROS levels) due to controlled

it has been shown that LUT induces apoptosis by promoting
antioxidant activity and activating MAPK signaling in human
colon cancer cells (Kang et al., 2017). Being a flavone, the
antioxidant activity of LUT is thought to possibly be exerted by its
chemical structure consisting of four phenolic hydroxyl groups
and C2=C3 double bond in conjugation with the C4-carbonyl
group (Cai et al., 2006; Vo et al., 2019). Docosahexaenoic
acid being a PUFA, showed a moderate ability reduce cellular
ROS levels in the present study, and hence, DHA may act
as a lipophilic antioxidant that can reach the mitochondrial
hydrophobic domains of ROS production in the brain. Despite
being a highly oxidizable polyunsaturated fatty acid, DHA is
concentrated as a naturally occurring omega-3-PUFA in neuronal
brain membranes where approximately 30–50% of total dry
weight of the brain is lipid. In fact, there are reports of DHA
on enzymatic antioxidant activities, such as catalase, glutathione
peroxidase (GPx) and glutathione reductase (GR) (Hossain et al.,
1999; Hashimoto et al., 2005).
The second highest potency of antioxidant activity was
observed with the D5 L5 U5 combination (Figure 1) accounting
for its ability to inhibit Aβ1−42 -induced toxicity effectively
(Jayatunga et al., 2021). The data showed that although UA could
reduce ROS, it offered the least protection compared to other
compounds. Previous work of UA has shown that it can decrease
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FIGURE 9 | The effect of the three-compound combination and its constituents on the levels of PINK1. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of PINK1 protein for all treatments. The relative density of
the bands was normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent
experiments. Differences are significant at g P < 0.001 vs. vehicle control, & P < 0.05 vs. Aβ1−42 -treated control.

can augment the mitochondrial spare respiratory capacity by
increasing mitochondrial biogenesis and antioxidant activities
(Yamamoto et al., 2016). Although it was compelling to verify
this effect for the compounds, in the present study itself, the
requirement of bioenergetic flux analyses to confirm whether the
compounds promoted enhanced oxygen consumption made it
beyond the scope of the study.
It has been shown in our previous studies that the time
of exposure of Aβ1−42 to cells is a crucial determinant
for inducing significant detrimental effects on mitochondrial
dynamics, mitophagy and mitobiogenesis (Jayatunga et al.,
unpublished). Therefore, 20 µM Aβ1−42 exposure time of 16 h
was selected to determine the time-dependent marked deficits
of mitochondrial dynamics, mitophagy and mitobiogenesis.
Mitochondrial dynamics-related proteins (OPA1, MFN2, and
FIS1), mitophagy-related proteins (p62, NDP52, OPTN, PINK1),
IMM protein TIMM23 and mitochondrial biogenesis protein
PGC-1α were analyzed using western blotting. Resveratrol was
used as a reference compound for its ability to induce mitophagy
(Kuno et al., 2018; Cao et al., 2019) and mitobiogenesis
(Csiszar et al., 2009).
In the present study, DHA was shown to have increased
L-OPA1, S-OPA1, and MFN2 levels implying its effects on
increasing mitochondrial fusion. The increased TIMM23 levels

reduction of MMP, is a highly effective antioxidant strategy
(Caldeira da Silva et al., 2008).
Therefore, the current study was designed to assess the ability
of the compounds to restore the ATP levels affected by the
administration of Aβ1−42 . As assessed at 4–72 h of Aβ1−42
exposure, the reduced ATP levels are increased by pre-treatment
with the compounds. Considering the activity of all the time
points, the overall order of potency of increasing the ATP
production by the compounds was, D5 L5 U5 > LUT > UA
(Figure 2). This order of potency was consistent over every time
point. The mechanism by which ATP levels were increased is
presently unclear, however the speculation is that the compounds
could accept electrons from oxidative species and transfer them
to cytochrome c, bypassing respiratory complexes I and III, at
a level sufficient to compensate for reduced proton pumping
(Komlódi and Tretter, 2017; Berry et al., 2018; Zhao et al., 2019).
Mitochondrial spare respiratory capacity is known to be an
important aspect of mitochondrial function and is defined as
the difference between basal ATP production and its maximal
activity (Deng et al., 2015; Pfleger et al., 2015). It accounts for
the extra ATP that can be produced by OXPHOS to overcome
various cellular stressors. A cell with a larger spare respiratory
capacity can produce more ATP and, in theory, overcome more
stress. It has been reported that various polyphenolic compounds
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FIGURE 10 | The effect of the three-compound combination and its components on the levels of TIMM23. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of TIMM23 protein for all treatments. Semi-quantitative
analysis of TIMM23 protein levels. The relative density of the bands was normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are
expressed as mean ± SD from four (N = 4) independent experiments. Differences are significant at @@@ P < 0.001 vs. Aβ1−42 -treated control.

p62, OPTN, PINK1 levels and decreased TIMM23
levels. It did not exert beneficial effects in inducing
mitobiogenesis, despite inducing mitochondrial fusion due
to increased L-OPA1 levels. These findings are in line
with previous reports indicating that LUT is an autophagy
or mitophagy inducing compound (Hu et al., 2016). In
contrary to the present study, it has also been reported
that LUT inhibited autophagy (Li et al., 2019) and induced
mitobiogenesis through inhibition of the Mst-1 pathway
(Hu et al., 2016).
The present study revealed that UA induced mitophagy
as indicated by increased expression levels of p62, NDP52,
OPTN, and PINK1. The OPA1 levels were also increased by UA
treatment, indicating increased mitochondrial fusion. However,
UA only exhibited a non-significant trend for raised PGC1α levels, indicating that mitobiogenesis was not occurring at
detectable levels. These findings of UA on inducing mitophagy
are in line with previous reports (Ryu et al., 2016; Webb, 2017).
Moreover, UA has shown to be beneficial in both Aβ and Tau
based Caenorhabditis elegans models of AD (Fang et al., 2019).
While one report states that UA stimulates autophagy but not
mitophagy to inhibit ER stress in a model of ischemic neuronal

suggest that DHA may inhibit mitophagy or promote biogenesis.
However, DHA induced mitophagy as well as mitobiogenesis
due to its ability to increase of p62, OPTN, PINK1 and
PGC-1α. Therefore, the increased TIMM23 levels denote the
excess mitochondria biosynthesized after compensation with
mitophagy. These findings are consistent with the previous
studies that have identified the role of DHA as a potential
mitophagy or autophagy inducer, or both (Jing et al., 2011; Shin
et al., 2013).
It has been reported that mitobiogenesis is related to sterol
regulatory element (SRE)-binding protein (SREBP-1c) as it
is implicated in upregulation of PGC-1α (Kobayashi et al.,
2018). However, it has been reported that DHA inhibits the
promoter activity of SREBP-1c (Deng et al., 2015; Huang et al.,
2017) suggesting that DHA may not promote mitobiogenesis
in that pathway. However, the present study resulted in an
outcome contrary to the above-mentioned studies by showing
DHA induced mitobiogenesis. However, the current findings are
consistent with several other reports that indicate mitobiogenesis
is induced by DHA (Flachs et al., 2005; Lee et al., 2016).
Luteolin also appears to act as an autophagy/mitophagy
inducer based on the present findings, due to increased
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FIGURE 11 | The effect of three-compound combination and its components on the levels of PGC1-α. The BE(2)-M17 cells were pre-treated for 24 h with the
three-compound combination, D5 L5 U5 , DHA (30 µM), LUT (20 µM), UA (30 µM), and RES (10 µM). The cells were then exposed to 20 µM of oligomeric Aβ1−42 for
16 h and subjected to Western blotting. The representative immunoblot and the graph indicate the levels of PGC1-α protein for all treatments. The relative density of
the bands was normalized against GAPDH. Fold values were calculated relative to vehicle control. Data are expressed as mean ± SD from four (N = 4) independent
experiments. Differences are significant at *P < 0.05, ***P < 0.001 vs. Aβ1−42 -treated control.

TABLE 1 | Changes in mitochondrial dynamics-related proteins, mitophagy-related proteins, and the mitobiogenesis-related protein with pre-treatment of compounds
followed by Aβ1−42 treatment.
Proteins

Aβ1−42 -control

D5 L5 U5

DHA (30 µM)

LUT (20 µM)

UA (30 µM)

RES (10 µM)

For all proteins, vehicle-treated control was considered as 1
Mitochondrial dynamics-related proteins
L-OPA1

-

–

+

+

+++

+

S-OPA1

–

-

+

–

++

++

MFN2

–

–

-

–

–

-

FIS1

-

–

–

-

-

+++

Mitophagy-related proteins
p62

–

-

+

++

+

NDP52

–

+

+

++

-

-

OPTN

–

–

+

-

++

+++

PINK1

–

–

-

-

-

-

TIMM23

+

+

+

-

-

-

++

+++

-

+

++

Mitochondrial biogenesis-related protein
PGC-1α

-

Using Western blotting, protein fold changes were assessed in BE(2)-M17 cells pre-treated with D5 L5 U5 , DHA, LUT, UA, and RES for 24 h followed by 20 µM oligomeric
Aβ1−42 exposure for 16 h. ± values indicate the relative protein fold change compared to vehicle controls.
Protein fold changes at 0.50–0.70: –, 0.71–0.99: -, 1.01–1.20: +, 1.21–1.40: ++, 1.41 upwards: +++.
Significant changes vs. Aβ1−42 -treated control are indicated by
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injury (Ahsan et al., 2019), our findings indicated that UA
induced both autophagy and mitophagy.
The present study revealed that pre-treatment with D5 L5 U5
increased NDP52 (P < 0.001), an autophagy adaptor protein
related to mitophagy, revealing its ability to trigger mitophagy.
In fact, D5 L5 U5 increased PGC-1α levels (P < 0.05) indicating
induction of mitobiogenesis. The increased trend of TIMM23 was
attributed to the mitochondrial mass balanced by mitobiogenesis
and mitophagy processes. It was also indicated that D5 L5 U5
increased S-OPA1 levels (P < 0.05). Apart from its action in
mitochondrial fission, as a prerequisite to mitophagy, S-OPA1 has
also been proposed to act as an enhancer of OPA1-Cardiolipin
interaction that facilitates mitochondrial fusion (Rujiviphat
et al., 2009). This may explain how the three-compound
combination, D5 L5 U5 , increased mitochondrial fusion to result
in increased mitobiogenesis.
The order of potency for mitophagy-inducing activity of
the compounds is UA > DHA > LUT > D5 L5 U5 . However,
the utility of inducing mitophagy is undoubtedly preferred
only in a controlled manner without causing deterioration
or toxicity in cellular respiration. In this regard, these
compounds also have strong antioxidant properties. Hence, it
is obvious that their mechanisms of activating mitophagy are
not ROS-dependent or mitohormetic, thus positioning them
as important candidates for potential AD therapy. Moreover,
considering the antioxidant properties determined through the
cellular ROS levels, the compounds can be positioned as
UA > DHA > D5 L5 U5 > LUT, suggesting a correlation between
the level of ROS and mitophagy only at higher levels of ROS.
It has been speculated that mitochondrial ROS (superoxide)
involves in mitophagy, but this notion remains to be verified
(Shefa et al., 2019; Schofield and Schafer, 2020). Further studies
are needed to investigate the molecular mechanisms by which the
three-compound combination reduces ROS levels and induces
mitophagy and mitobiogenesis.
Compounds that activate mitophagy without inducing
a respiration collapse are important as protectors of
mitochondria. The three-compound combination, D5 L5 U5

effectively attenuated Aβ1−42 -induced toxicity (Jayatunga et al.,
2021), possibly due its ability to decrease ROS levels, induce
mitobiogenesis and mitophagy, to some extent. In fact, D5 L5 U5
was shown to have its protective ability on all aspects tested,
namely, by reducing ROS levels, increasing ATP levels, and
inducing mitophagy and mitobiogenesis. Taken together, having
DHA, LUT, and UA in one single entity as D5 L5 U5 immensely
benefits and precedes the mitochondrial protective role as shown
in the current study. It is of note that there may be other
pathways that may account for the neuroprotection exerted by
this synergistic nutraceutical combination. Further in vitro and
in vivo studies are required to uncover the specific modes of
mitophagy and mitobiogenesis elicited by the D5 L5 U5 .
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